Interní Med. 2005; 7(5): 250-254

Inflammatory bowel disease and colorectal cancer

prof. MUDr. Milan Lukáš CSc1, MUDr. Ivana Vítková2, MUDr. Martin Bortlík2, MUDr. Milada Kohoutová3
1 IV. interní klinika VFN a 1. LF UK, Praha
2 Ústav patologie 1. LF UK, Praha
3 Ústav biologie a lékařské genetiky 1. LF UK a VFN, Praha

Colorectal cancer represents serious complication of inflammatory bowel disorders (IBD), Crohn´s disease and ulcerative colitis. Colorectal cancer is associated with each sixth deaths in IBD patients. The authors in this review summarise the current opinion on the pathogenesis and early diagnosis dysplastic lesions and colorectal cancer. There are discussed risk factors which induce to the next development of dysplasia. The most important are: long term course of disease and extensive involvement of the large bowel. The extraordinary risk of colorectal cancer is asscociated with primary sclerosing cholangitis

Keywords: Key words: inflammatory bowel disease, colorectal cancer, dysplasia, Crohn´s disease, ulcerative colitis.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáš M, Vítková I, Bortlík M, Kohoutová M. Inflammatory bowel disease and colorectal cancer. Interní Med. 2005;7(5):250-254.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bernstein CN, Shanahan F, Einstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-74. Go to original source... Go to PubMed...
    2. Blackstone MO, Riddell RH, Rogers BHG, et al. Dysplasia associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981; 80: 366-374. Go to original source...
    3. Eaden J, Abrams KR, Maybery JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535. Go to original source... Go to PubMed...
    4. Ekbom A, Helmick C, Zach M, Adam HO. Ulcerative colitis and colorectal cancer. N Engl J Med, 1990; 323: 1227-1233. Go to original source... Go to PubMed...
    5. Gagot D, Anen D. Primary prevention of colorectal cancer: diet and drug. In: Clinical Management of Premalignant Disorders of the Gastrointestinal Tract. Edited by:Julian Katz and James C.Reynolds: Gastroentrerol Clin N Am 2002; 31: 587-623. Go to original source...
    6. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel disease. Gastroenterology 2004; 126: 1634-1648. Go to original source... Go to PubMed...
    7. Kieslisch R, Fritsch J, Holmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepitelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888. Go to original source... Go to PubMed...
    8. Kornfeld D, Ekbom A, Ihre T. Is there excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41: 522-525. Go to original source... Go to PubMed...
    9. Pardi DS, Lotus EV, Kremers WK, at al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893. Go to original source... Go to PubMed...
    10. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.